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background: Atrial fibrillation is the most commonly encountered sustained cardiac arrhythmia in medical practice and it is often 
associated with thromboembolic complications. Biotronik home monitoring (HM) technology provides relevant notifications for detection of 
supra-ventricular arrhythmias (SVA). The SETAM randomized, multicenter trial assessed the impact of HM on detection and treatment of 
SVA.
Methods:  Patients implanted with a dual chamber pacemaker were enrolled in the study at hospital discharge if they had a sinusal rhythm 
at enrollment, no antiarrhythmic, anticoagulant or dual-antiplatelet therapy, and if they had a CHA2DS2-VASc score for stroke risk of 2 or 
more. The patients were randomly assigned to an active group, followed by HM, or a control group without HM surveillance. The time from 
implantation to the first treatment for SVA (drugs or ablation) as well as mean atrial burden (% of time over 24 hours during which atrial rate 
is >200bpm) were compared between the groups.
results:  A total of 595 patients (mean age = 79 ± 8 y.o, 63% male, mean CHA2DS2-VASc score = 3.7 ± 1.2) were followed during 12.8 
± 3.3 months. There was no difference in the baseline clinical characteristics between the groups. The global SVA incidence was 29% 
in the active group vs 21% in the control group, p=ns. A treatment was instituted for 49/291 patients (16%) in the active group vs 43/304 
patients (14%) in the control group, p=ns. Anticoagulation and antiarrhythmic drugs were initiated in 75% and 49% of patients respectively, 
without significant difference between the groups. The time to manage SVA was reduced by 44% with remote monitoring (HR=0.565, 
95%CI=[0.370; 0.864], p=0.01). Among the patients receiving a treatment, 75% were free of SVA at end of study in the active group vs 41% 
in the control group (p<0.01). At 12 months post-implantation, mean atrial burden in the active group was 7 ± 22% (1h41 per day) vs 30 ± 
44% (7h12 per day) in the control group (p=0.01), representing a difference of 5.5 hours per day.
Conclusion:  The SETAM study provided evidence that early detection and treatment of SVA reduced atrial burden in pacemaker patients 
followed by HM.
